


**INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	of	2	Attorney Docket Number	34848/194868
MAY 13 2002				



U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
T.S.	8	6,024,977		Yatvin et al.	02/2000	
	9	4,179,337		Davis et al.	12/18/1979	
	10	4,462,941		Lee et al.	07/31/1984	
	11	4,468,383		Rodbard et al.	08/28/1984	
	12	4,518,711		Hruby et al.	05/21/1985	
	13	4,684,624		Hosobuchi et al.	08/04/1987	
	14	4,902,505		Pardridge et al.	02/20/1990	
	15	5,017,689		Hruby et al.	05/21/1991	
	16	5,326,751		Haaseth et al.	07/05/1994	
	17	5,442,043		Fukuta et al.	08/15/1995	
	18	5,629,384		Veronese et al.	05/13/1997	
	19	5,631,322		Veronese et al.	05/20/1997	
	20	5,833,988		Friden	11/10/1998	
	21	5,932,462		Harris et al.	08/03/1999	
	22	5,990,237		Bentley et al.	11/23/1999	
T.S.	23	6,362,254		Harris et al.	03/26/2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document		Kind Code Office ³ Number ⁴ (if known) ⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
T.S.	24	WO	96/23794		Enzon, Inc.	08/08/1996		

Examiner Signature	T.S. Bentley et al.	Date Considered	5/23/02
--------------------	---------------------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁶ Applicant is to place an "X" here if English language Translation is attached.

Substitute for form 1449A/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	09/678,997
			Filing Date	October 4, 2000
			First Named Inventor	Bentley et al.
			Group Art Unit	4656 (C 57) MAY 9 2001
			Examiner Name	
Sheet 1 of 2	Attorney Docket Number	34848/194868		

MAY 13 2002

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Patent No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
T S	25	Maeda et al., "Amino Acids and Peptides. XXIV. Preparation and Antinociceptive Effects of [D-Ala ² , (N-Me)Phe ⁵]Enkephalin Analog-Poly(Ethylene Glycol) Hybrids," <u>Chem. Pharm. Bull.</u> , Vol. 42, pp. 1859-1863 (1994)	
	26	Munson et al. (editor), "Principles of Pharmacology," Chapman and Hall, pp. 43-48, 1995	
	27	Kurihara, A. et al., "Epidermal Growth Factor Radiopharmaceuticals: 111In Chelation, Conjugation to a Blood Brain Barrier Delivery Vector via a Biotin-Polyethylene Linker,..." <u>Bioconjugate Chem.</u> , vol. 10, pp. 502-511, May 17, 1995	
	28	Pardridge, "Physiologic-bases strategies for protein drug delivery to the brain," <u>Journal of Controlled Release</u> , 39 pp. 281-286 (1996)	
	29	Brownlees et al., "Peptidases, Peptides, and the Mammalian Blood-Brain Barrier," <u>Journal of Neurochemistry</u> , Vol. 60, No. 3, pp. 793-803 (1993)	
	30	Friden, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," <u>Journal of Controlled Release</u> , 46, pp. 117-128 (1996)	
	31	Pardridge et al., "Combined Use of Carboxyl-Directed Protein Pegylation and Vector-Mediated Blood-Brain Barrier Drug Delivery System Optimizes Brain Uptake of Brain-Derived Neurotrophic Factor Following Intravenous Administration," <u>Pharmaceutical Research</u> , Vol. 15, No. 4, pp. 576-582 (1998)	
	32	Kawasaki et al., "Amino Acids and Peptides. XIX. Preparation of Enkephalin-Poly(Ethylene Glycol) Hybrid and Evaluation of Its Analgesic Activity," <u>Chem. Pharm. Bull.</u> , 41(11) pp 2053-2054 (1993)	
	33	Maeda et al., "Amino Acids and Peptides. XXII. Preparation and Antinociceptive Effect of [D-Ala ²]Leu-Enkephalin-Poly(Ethylene Glycol) Hybrid," <u>Chem. Pharm. Bull.</u> , 17(6) pp 823-825 (1994)	
	34	Williams et al., "Passage of a δ-Opioid Receptor Selective Enkephalin, [D-Penicillamine ^{2,5}] Enkephalin, Across the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers," <u>J. of Neurochemistry</u> , vol. 66, No. 3, pp. 1289-1299 (1996)	
	35	Zalipsky, "Chemistry of polyethylene glycol conjugates with biologically active molecules," <u>Advanced Drug Delivery Review</u> , 16, pp. 157-182 (1995)	
	36	Zalipsky et al., "Copolymers of Lysine and Polyethylene Glycol: A New Family of Functionalized Drug Carriers," <u>Bioconjugate Chem.</u> , Vol. 4, No. 1, pp. 54-62 (1993)	
	37	Hruby et al., "Recent Developments in the Design of Receptor Specific Opioid Peptides," <u>Medicinal Research Review</u> , Vol. 9, No. 3, pp. 343-401 (1989)	

Examiner Signature	T. S. Shukla	Date Considered	5/13/02
--------------------	--------------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. CLT01/4533408v1